Filtered By:
Specialty: Hematology
Condition: Hemorrhagic Stroke

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 295 results found since Jan 2013.

Adult and pediatric mechanical circulation: a guide for the hematologist.
Authors: Kreuziger LB, Massicotte MP Abstract Mechanical circulatory support (MCS) is the overarching term that encompasses the temporary and durable devices used in patients with severe heart failure. MCS disturbs the hematologic and coagulation system, leading to platelet activation, activation of the contact pathway of coagulation, and acquired von Willebrand syndrome. Ischemic stroke and major hemorrhage occur in up to 30% of patients. Hematologists are an essential part of the MCS team because they understand the delicate balance between bleeding and clotting and alteration of hemostasis with antithrombotic th...
Source: Hematology ASH Education Program - December 7, 2018 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Use of Tranexamic Acid in an Uncommon Triad: Hemorrhagic Stroke, Sickle Cell Disease and Severe Coagulopathy
No abstract available
Source: Journal of Pediatric Hematology Oncology - February 21, 2019 Category: Hematology Tags: Letter to the Editor Source Type: research

Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study
AbstractAtrial fibrillation (AF) is the most common arrhythmia in clinical practice and its prevalence increases with age. Few data are available about the clinical performance of direct oral anticoagulant (DOACs) in patients aged  ≥ 80 years with AF. The aim of our propensity score matched cohort study was to compare the safety and efficacy of DOACs versus well-controlled VKA therapy among octogenarians with AF in real life setting. Data for this study were sourced from the multicenter prospectively maintained Atrial Fibrillation Research Database (NCT03760874), which includes all AF patients followed by the partic...
Source: Journal of Thrombosis and Thrombolysis - August 4, 2019 Category: Hematology Source Type: research

A case of an extreme white coat effect.
In this report, we present a challenging case of a 63-year-old Caucasian woman with an extreme stress response to blood pressure (BP) measurements. Office- and ambulatory BP measurements consistently found systolic BP above 200 mmHg. However, antihypertensive medication made her dizzy and extremely unwell, and she could barely tolerate treatment with a moderate dose of angiotensin-converting enzyme (ACE) inhibitor. Finger-cuff-based measurements (Finapres Finometer®) revealed extreme hypertension in relation to contact with medical professionals, but hypotension when the patient was seated alone unobserved. Months after...
Source: Blood Pressure - August 29, 2019 Category: Hematology Tags: Blood Press Source Type: research

Outcomes of direct oral anticoagulant- and warfarin-associated hemorrhage: A single center retrospective cohort study
Direct oral anticoagulants (DOACs) are now a mainstay of anticoagulant therapy for the prevention and treatment of venous thromboembolism (VTE) and stroke prevention in non-valvular atrial fibrillation (a-fib). However, bleeding-related morbidity and mortality remains a feared complication. Bleeding in patients taking DOACs in clinical trials showed comparable, if not more favorable, outcomes compared to that of warfarin [1 –4]. However, the safety of DOAC use should also be evaluated in less selected cohorts in the real-world.
Source: Thrombosis Research - September 2, 2019 Category: Hematology Authors: Lorraine Cafuir, En Cheng, Christine Kempton Tags: Letter to the Editors-in-Chief Source Type: research

OC1. Abstract Title: In-hospital Mortality and Morbidity among Patients Presenting with Intracranial Hemorrhage: A Single Center's Experience with Vitamin K Antagonists and the Direct Oral Anticoagulants
Oral anticoagulants are the preferred therapy for the treatment of venous thromboembolism and for stroke prevention among patients with atrial fibrillation. Given their widespread use, clinicians must balance efficacy of anticoagulation with their associated bleeding risks. Specifically, intracranial hemorrhage (ICH) is the most feared complication as this form of bleeding has the highest mortality and morbidity. To date, clinical trials suggest a lower incidence of ICH and better safety profile among patients prescribed the direct oral anticoagulants (DOACs) compared with traditional vitamin k antagonists (VKAs).
Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: C. Cipkar, S. Srinathan, P. Chiang, L. Castellucci Tags: Oral Communications Source Type: research

Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and rivaroxaban in atrial fibrillation
Direct oral anticoagulants (DOACs) have been proven non-inferior or superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major hemorrhage, in patients with non-valvular atrial fibrillation (NVAF). We sought to investigate whether effectiveness and safety differs among apixaban, rivaroxaban and dabigatran.
Source: Thrombosis Research - November 12, 2019 Category: Hematology Authors: M. Jansson, S. Sj älander, V. Sjögren, H. Renlund, B. Norrving, A. Själander Tags: Full Length Article Source Type: research

Evaluation of long-term rt-PA effects on bEnd.3 endothelial cells under ischemic conditions; changes in ZO-1 expression and glycosylation of the bradykinin B2 receptor
Recombinant tissue plasminogen activator (rt-PA) has proven effective in the treatment of acute ischemic stroke, despite the increased risk of hemorrhagic transformation (HT), its major associated complication. Although it is known that HT is related to blood brain barrier (BBB) disruption, the underlying mechanisms are not well established. We assessed time-dependent effects of rt-PA on the bEnd.3 murine brain endothelial cell line subjected either to normoxia or to 2.5  h of oxygen and glucose deprivation (OGD), evaluating a longer period than has previously been done, beyond 6 h post-reoxygenation.
Source: Thrombosis Research - January 5, 2020 Category: Hematology Authors: Carme Gubern, Pau Comajoan, Gemma Huguet, Juan Manuel S ánchez, Joaquín Serena, Elisabet Kádár, Mar Castellanos Tags: Full Length Article Source Type: research

Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis
Anticoagulation in a neonate is a challenge and the availability of anticoagulant options is extremely limited. Here we describe the use of a direct thrombin inhibitor, bivalirudin, in a full-term neonate with symptomatic cerebral sinovenous thrombosis complicated by bilateral thalamic hemorrhagic stroke and intraventricular hemorrhage, who could not be effectively treated with sodium heparin due to heparin resistance (HR) and showed thrombosis regression after start of bivalirudin treatment, without worsening of the hemorrhage. While the use of bivalirudin in neonates has been previously described, the indication of cereb...
Source: Blood Coagulation and Fibrinolysis - January 1, 2020 Category: Hematology Tags: CASE REPORTS Source Type: research

Oral Anticoagulation in the Elderly and Frail.
In conclusion, elderly and frail patients requiring anticoagulation for AF or VTE are at higher risk of adverse outcomes, but also have a higher absolute benefit from OAC. Important practical aspects to improve efficacy and safety in this challenging population are summarized in this overview. PMID: 32000266 [PubMed - as supplied by publisher]
Source: Hamostaseologie - January 29, 2020 Category: Hematology Authors: Bauersachs RM, Herold J Tags: Hamostaseologie Source Type: research

Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI.
Authors: Wang HY, Gao RL, Xu B, Yang YJ, Yin D, Wang Y, Dou KF Abstract The benefits and harms of dual antiplatelet therapy (DAPT) continuation with aspirin and clopidogrel beyond 1 year after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation for high ischemic or bleeding risk patients remain unclear. All consecutive patients undergoing PCI were prospectively included in the Fuwai PCI Registry from January 2013 to December 2013. We evaluated 7521 patients who were at high risk for thrombotic or hemorrhagic complications and were events free at 1 year after the index procedure. "TWI...
Source: Platelets - June 7, 2020 Category: Hematology Tags: Platelets Source Type: research

Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood
AbstractDabigatran etexilate is an oral direct thrombin (Factor IIa) inhibitor approved for patients with atrial fibrillation and for management of risk of deep vein thrombosis and pulmonary embolism. Dabigatran offers advantages over treatment with warfarin, including limited laboratory monitoring. It is equivalent in prevention of stroke and deep vein thrombosis with essentially equivalent complication rates. In contrast to warfarin, reversal of the anticoagulation is less well established. Idarucizumab is available for reversal, however supporting research is mixed; the agent also happens to be quite expensive making av...
Source: Indian Journal of Hematology and Blood Transfusion - June 21, 2020 Category: Hematology Source Type: research

Evaluation of Oral Factor Xa inhibitor-associated Extracranial Bleeding Reversal with Andexanet alfa.
CONCLUSION: We report poor overall outcomes, a low rate of hemostatic effectiveness, and a high rate of ischemic complications and mortality in this retrospective analysis of oral FXa inhibitor reversal with andexanet alfa for extracranial bleeds. More rigorous epidemiological, and ideally randomized studies are needed to determine the role of andexanet alfa for FXa inhibitor-associated bleeding for extracranial hemorrhages, where large variation in severity and presentation exists. PMID: 32738161 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 31, 2020 Category: Hematology Authors: Nederpelt CJ, Naar L, Sylvesterc KW, Barra ME, Roberts RJ, Velmahos GV, Kaafarani HMA, Rosenthal MG, King DR Tags: J Thromb Haemost Source Type: research

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19
Covid-19 has significant implications of hematologic systems, including lymphocytopenia, thrombocytopenia, ischemic or hemorrhagic stroke, pulmonary thromboembolism, and myocardial infarction [1,2]. Iwasaki et al. reported that the pathogen of Covid-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can induce immune dysfunction, inflammation, and antibody-dependent enhancement by activating host cells via the Fc γIIa receptor in the same way as SARS-CoV-1 [3].
Source: Thrombosis Research - August 2, 2020 Category: Hematology Authors: Ching-Tai Huang, Shao-Yun Hsu, Ko-Wei Chang, Chung-Guei Huang, Cheng-Ta Yang, Ming-Huei Cheng Tags: Letter to the Editors-in-Chief Source Type: research

Reversible Cerebral Vasoconstriction Syndrome and Sickle Cell Disease: A Case Report
In this report, we focus on the typical features of RCVS and discuss the underlying risk factors that may increase the risk in patients with HbSS disease.
Source: Journal of Pediatric Hematology Oncology - December 16, 2020 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research